Roche's Lunsumio plus lenalidomide meets Phase III PFS endpoint in FL

Roche has reported that its Phase III CELESTIMO trial of Lunsumio (mosunetuzumab) in combination with lenalidomide met its primary endpoint at an interim analysis, delivering a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory follicular lymphoma who had received at least one prior line of treatment.

The comparator arm used rituximab plus lenalidomide, a widely used standard-of-care doublet in this setting. Overall survival data were immature at the time of the interim readout, and Roche has not yet released the underlying PFS figures, hazard ratio, or detailed safety breakdown. The company said the safety profile of the combination was consistent with the known profiles of each individual agent, with no new signals identified. Full data will be submitted to health authorities and presented at an upcoming medical conference.

Regulatory significance

CELESTIMO is not a purely exploratory study. Roche designed it as a confirmatory trial required by regulators to convert Lunsumio's accelerated approval in the United States and conditional marketing authorisation in other jurisdictions from a third-line-or-later (3L+) indication into a full approval, and to secure a broader second-line-or-later (2L+) label. A positive readout therefore carries direct commercial and regulatory weight beyond the science alone.

Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the results indicate that "a two-drug outpatient Lunsumio regimen may offer these patients an effective new option earlier in their treatment journey." The outpatient, fixed-duration administration of the combination is being positioned as a practical differentiator against regimens that require more intensive hospital attendance.

Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that simultaneously targets CD20 on malignant B cells and CD3 on the patient's own T cells, redirecting an endogenous immune response to eliminate tumour cells. It is already approved in over 60 countries for 3L+ follicular lymphoma and has been used in more than 3,800 patients.

Market and competitive context

The bispecific antibody space in B-cell lymphomas has grown sharply more competitive over the past two years. Regeneron's odronextamab and Genmab and AbbVie's epcoritamab both target CD20xCD3, and AstraZeneca and Daiichi Sankyo are advancing antibody-drug conjugates into overlapping lymphoma indications. The CELESTIMO data, once presented in full, will need to show a durable PFS benefit relative to rituximab-lenalidomide to strengthen Lunsumio's commercial position against this expanding field.

Roche is simultaneously pursuing broader expansion of Lunsumio across haematological malignancies. The FDA recently accepted a supplemental Biologics Licence Application for Lunsumio combined with Polivy (polatuzumab vedotin) in second-line diffuse large B-cell lymphoma, based on the SUNMO study. The Phase III MorningLyte study is evaluating the agent in the first-line follicular lymphoma setting, meaning a successful regulatory conversion from CELESTIMO would slot Lunsumio into an increasingly broad treatment continuum.

Follicular lymphoma affects an estimated 110,000 people annually worldwide and, while often responsive to initial therapy, is characterised by repeated relapse with generally diminishing responses over time. Moving an effective regimen earlier in the treatment course is a longstanding clinical priority, and analysts will watch the CELESTIMO data presentation closely to assess whether the PFS benefit translates to meaningful overall survival signals as follow-up matures.